PE20190414A1 - Derivados de oxadiazolopiridina para el uso como inhibidores de ghrelin o-aciltransferasa (goat) - Google Patents

Derivados de oxadiazolopiridina para el uso como inhibidores de ghrelin o-aciltransferasa (goat)

Info

Publication number
PE20190414A1
PE20190414A1 PE2019000271A PE2019000271A PE20190414A1 PE 20190414 A1 PE20190414 A1 PE 20190414A1 PE 2019000271 A PE2019000271 A PE 2019000271A PE 2019000271 A PE2019000271 A PE 2019000271A PE 20190414 A1 PE20190414 A1 PE 20190414A1
Authority
PE
Peru
Prior art keywords
ghrelin
goat
aciltransferase
inhibitors
oxadiazolopyridine derivatives
Prior art date
Application number
PE2019000271A
Other languages
English (en)
Inventor
Cedrickx Godbout
Thomas Trieselmann
Viktor Vintonyak
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PE20190414A1 publication Critical patent/PE20190414A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Referido a derivados de oxadiazolopiridina de formula (I), en donde X es CH o N; R1 se selecciona entre CH3, -CH2OH y Cl; R2 se selecciona, independientemente entre si, entre H, F, Cl, Br, I, CN, C1-6-alquilo, C3-7-cicloalquilo, entre otros; n es 1, 2 o 3. Estos compuestos se fijan a ghrelin O-acil transferasa (GOAT) e inhiben su actividad. Tambien se refiere a metodos de fabricacion y su uso adecuado para el tratamiento y la prevencion de enfermedades, tales como enfermedades metabolicas, diabetes mellitus tipo 2, la obesidad, entre otros.
PE2019000271A 2016-08-05 2017-07-31 Derivados de oxadiazolopiridina para el uso como inhibidores de ghrelin o-aciltransferasa (goat) PE20190414A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16183047 2016-08-05

Publications (1)

Publication Number Publication Date
PE20190414A1 true PE20190414A1 (es) 2019-03-19

Family

ID=56609762

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019000271A PE20190414A1 (es) 2016-08-05 2017-07-31 Derivados de oxadiazolopiridina para el uso como inhibidores de ghrelin o-aciltransferasa (goat)

Country Status (32)

Country Link
US (3) US9994591B2 (es)
EP (1) EP3494120B1 (es)
JP (1) JP6651054B2 (es)
KR (1) KR102496075B1 (es)
CN (1) CN109843891B (es)
AR (1) AR109296A1 (es)
AU (1) AU2017307033B2 (es)
CA (1) CA3033058A1 (es)
CL (1) CL2019000274A1 (es)
CO (1) CO2019000601A2 (es)
CY (1) CY1124381T1 (es)
DK (1) DK3494120T3 (es)
EA (1) EA037277B1 (es)
ES (1) ES2874587T3 (es)
HR (1) HRP20210908T1 (es)
HU (1) HUE054928T2 (es)
IL (1) IL264506B (es)
LT (1) LT3494120T (es)
MA (1) MA45843B1 (es)
MX (1) MX2019001427A (es)
MY (1) MY197064A (es)
PE (1) PE20190414A1 (es)
PH (1) PH12019500254A1 (es)
PL (1) PL3494120T3 (es)
PT (1) PT3494120T (es)
RS (1) RS61937B1 (es)
SA (1) SA519401039B1 (es)
SG (1) SG11201811804QA (es)
SI (1) SI3494120T1 (es)
TW (1) TWI749042B (es)
UA (1) UA124267C2 (es)
WO (1) WO2018024653A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7225253B2 (ja) * 2018-02-02 2023-02-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グレリンo-アシルトランスフェラーゼ(goat)阻害剤として使用するためのピラゾール置換及びインダゾール置換オキサジアゾロピリジン誘導体
AU2019215709A1 (en) * 2018-02-02 2020-07-16 Boehringer Ingelheim International Gmbh Heterocyclyl-substituted oxadiazolopyridine derivatives for use as ghrelin O-acyl transferase (GOAT) inhibitors
SG11202006125VA (en) * 2018-02-02 2020-07-29 Boehringer Ingelheim Int Benzyl-, (pyridin-3-yl)methyl- or (pyridin-4-yl)methyl-substituted oxadiazolopyridine derivatives as ghrelin o-acyl transferase (goat) inhibitors
MX2020007994A (es) 2018-02-02 2020-09-09 Boehringer Ingelheim Int Derivados de triazolopirimidina para usar como inhibidores de ghrelin o-aciltransferasa (goat).
EP4153599B1 (en) 2020-05-22 2024-03-13 Boehringer Ingelheim International GmbH Process for manufacturing alkyl 7-amino-5-methyl-[1,2,5]oxadiazolo[3,4-b]pyridine-carboxylate
JP2023526353A (ja) 2020-05-22 2023-06-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アルキル7-アミノ-5-メチル-[1,2,5]オキサジアゾロ[3,4-b]ピリジンカルボキシレートの連続製造方法
CN112014340A (zh) * 2020-09-01 2020-12-01 广西玮美生物科技有限公司 非人灵长类动物胃饥饿素的检测方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2241496B1 (es) 2004-04-15 2006-12-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridina.
CL2007003580A1 (es) 2006-12-11 2009-03-27 Boehringer Ingelheim Int Compuestos derivados de piridazina, antagonistas de mch; composicion farmaceutica que comprende a dicho compuesto; procedimiento de preparacion; y uso del compuesto en el tratamiento de trastornos metabolicos y/o trastornos alimentarios como obesidad, bulimia, anorexia, hiperfagia, diabetes.
CN101790538B (zh) 2007-02-15 2014-07-30 印第安纳大学研究与科技公司 胰高血糖素/glp-1受体共激动剂
US7994122B2 (en) 2007-06-15 2011-08-09 Zealand Pharma A/S Glucagon analogues
JP5635530B2 (ja) 2008-12-15 2014-12-03 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
CA2747155A1 (en) 2008-12-15 2010-06-24 Zealand Pharma A/S Glucagon analogues
MA32970B1 (fr) 2008-12-15 2012-01-02 Zealand Pharma As Analogues du glucagon
JP5635532B2 (ja) 2008-12-15 2014-12-03 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
SG177609A1 (en) 2009-07-13 2012-02-28 Zealand Pharma As Acylated glucagon analogues
AR081975A1 (es) 2010-06-23 2012-10-31 Zealand Pharma As Analogos de glucagon
US9169310B2 (en) 2010-06-24 2015-10-27 Zealand Pharma A/S Glucagon analogues
BR112014015681A2 (pt) 2011-12-23 2019-09-24 Boehringer Ingelheim Int análogos de glucagon
CN104254525B (zh) * 2012-02-24 2016-05-25 武田药品工业株式会社 芳环化合物
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
UA118034C2 (uk) * 2013-11-14 2018-11-12 Елі Ліллі Енд Компані Заміщений піперидилетилпіримідин як інгібітор грелін-o-ацилтрансферази
WO2016044467A1 (en) * 2014-09-17 2016-03-24 The Regents Of The University Of California Small lipopeptidomimetic inhibitors of ghrelin o-acyl transferase
AR104672A1 (es) 2015-04-15 2017-08-09 Lilly Co Eli Inhibidores de grelina o-aciltransferasa
AR104673A1 (es) 2015-04-15 2017-08-09 Lilly Co Eli Inhibidores de grelina o-aciltransferasa
MX2020007994A (es) 2018-02-02 2020-09-09 Boehringer Ingelheim Int Derivados de triazolopirimidina para usar como inhibidores de ghrelin o-aciltransferasa (goat).
SG11202006125VA (en) 2018-02-02 2020-07-29 Boehringer Ingelheim Int Benzyl-, (pyridin-3-yl)methyl- or (pyridin-4-yl)methyl-substituted oxadiazolopyridine derivatives as ghrelin o-acyl transferase (goat) inhibitors
AU2019215709A1 (en) 2018-02-02 2020-07-16 Boehringer Ingelheim International Gmbh Heterocyclyl-substituted oxadiazolopyridine derivatives for use as ghrelin O-acyl transferase (GOAT) inhibitors
JP7225253B2 (ja) * 2018-02-02 2023-02-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グレリンo-アシルトランスフェラーゼ(goat)阻害剤として使用するためのピラゾール置換及びインダゾール置換オキサジアゾロピリジン誘導体

Also Published As

Publication number Publication date
US20180037594A1 (en) 2018-02-08
US10308667B2 (en) 2019-06-04
US9994591B2 (en) 2018-06-12
IL264506B (en) 2021-03-25
EA201990418A1 (ru) 2019-08-30
AR109296A1 (es) 2018-11-14
KR102496075B1 (ko) 2023-02-06
MY197064A (en) 2023-05-24
KR20190035859A (ko) 2019-04-03
EP3494120A1 (en) 2019-06-12
MX2019001427A (es) 2019-06-10
PT3494120T (pt) 2021-05-26
PL3494120T3 (pl) 2021-09-20
MA45843A (fr) 2019-06-12
LT3494120T (lt) 2021-05-25
SG11201811804QA (en) 2019-01-30
DK3494120T3 (da) 2021-05-31
TWI749042B (zh) 2021-12-11
EA037277B1 (ru) 2021-03-03
EP3494120B1 (en) 2021-03-17
HRP20210908T1 (hr) 2021-09-03
AU2017307033B2 (en) 2020-11-26
SA519401039B1 (ar) 2021-11-25
WO2018024653A1 (en) 2018-02-08
PH12019500254A1 (en) 2019-06-03
CA3033058A1 (en) 2018-02-08
CN109843891A (zh) 2019-06-04
NZ749290A (en) 2021-08-27
JP2019524786A (ja) 2019-09-05
RS61937B1 (sr) 2021-07-30
USRE49446E1 (en) 2023-03-07
SI3494120T1 (sl) 2021-08-31
MA45843B1 (fr) 2021-06-30
CY1124381T1 (el) 2022-07-22
CN109843891B (zh) 2021-11-23
CO2019000601A2 (es) 2019-02-08
UA124267C2 (uk) 2021-08-18
US20180251476A1 (en) 2018-09-06
JP6651054B2 (ja) 2020-02-19
IL264506A (en) 2019-02-28
HUE054928T2 (hu) 2021-10-28
ES2874587T3 (es) 2021-11-05
AU2017307033A1 (en) 2019-01-17
TW201817735A (zh) 2018-05-16
CL2019000274A1 (es) 2019-05-03

Similar Documents

Publication Publication Date Title
PE20190414A1 (es) Derivados de oxadiazolopiridina para el uso como inhibidores de ghrelin o-aciltransferasa (goat)
CO2020010465A2 (es) Compuestos para el tratamiento de trastornos dependientes de cinasas
CR11183A (es) Espirociclos como inhibidores de la 11-beta hidroxiesteroide deshidrogenasa de tipo 1
PE20190518A1 (es) Inhibidores de diacilglicerol aciltransferasa 2
UY37272A (es) Piridinas sustituidas con heteroarilo y métodos de uso
DOP2017000066A (es) Compuestos y composiciones como inhibidores de quinasa raf
CU20160188A7 (es) Compuestos de indazole substituidos como inhibidores de irak4
GT201300324A (es) Nuevos compuestos inhibidores de la fosfodiesterasa tipo 10a
CU20160149A7 (es) Compuestos de heteroarilo o arilo bicíclicos fusionados y su uso como inhibidores de irak4
PA8848201A1 (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes
CL2009000650A1 (es) Compuestos derivados de amino-pirazina, inhibidores de cinasa-pi 3; composicion farmaceutica; y uso para el tratamiento de condiciones inflamatorias o alérgicas, tales como enfermedades respiratorias, artritis reumatoide, colitis ulcerativa, entre otras
PE20180024A1 (es) Triazolopirazinonas como inhibidores de pde1
CR20130409A (es) Novedosos derivados de azabencimidazolcíclico útiles como agentes antidiabéticos
GT201400089A (es) Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a
PE20211782A1 (es) Compuestos de 5-cloro-2-difluorometoxifenil pirazolopirimidina, composiciones y metodos de uso de los mismos
CU20160120A7 (es) Benzimidazol-2-aminas como inhibidores de midh1
CU20090132A7 (es) Compuestos tricíclicos, composiciones y procedimientos
CO2018005315A2 (es) Moduladores de la interacción de sestrina-gator2 y sus usos
PA8809001A1 (es) Compuestos organicos
CO2020002961A2 (es) Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre
ECSP13012596A (es) Proceso de elaboración para derivados de pirimidina
SV2011003809A (es) Derivados de heteroarilo como inhibidores de dgat1
PE20191103A1 (es) Inhibidores de dopamina-b-hidroxilasa
UY37774A (es) Compuestos 5-cianoindol sustituidos y usos de los mismos
PE20141940A1 (es) Compuestos triciclicos, composiciones que los comprenden y usos de los mismos